MX2016013668A - Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. - Google Patents

Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.

Info

Publication number
MX2016013668A
MX2016013668A MX2016013668A MX2016013668A MX2016013668A MX 2016013668 A MX2016013668 A MX 2016013668A MX 2016013668 A MX2016013668 A MX 2016013668A MX 2016013668 A MX2016013668 A MX 2016013668A MX 2016013668 A MX2016013668 A MX 2016013668A
Authority
MX
Mexico
Prior art keywords
uses
irak inhibitors
inhibitors
irak
compounds
Prior art date
Application number
MX2016013668A
Other languages
English (en)
Inventor
E Masse Craig
robert greenwood Jeremy
L Romero Donna
Robinson Shaughnessy
Shelley Mee
C Harriman Geraldine
Original Assignee
Nimbus Iris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201461982645P priority Critical
Application filed by Nimbus Iris Inc filed Critical Nimbus Iris Inc
Priority to PCT/US2015/026876 priority patent/WO2015164374A1/en
Publication of MX2016013668A publication Critical patent/MX2016013668A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in positions 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente invención se refiere a compuestos de quinazolina y quinolina, composiciones de los mismos, y métodos para usar los mismos. También se describe la actividad de tales compuestos como inhibidores de las enzimas de IRAK.
MX2016013668A 2014-04-22 2015-04-21 Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. MX2016013668A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201461982645P true 2014-04-22 2014-04-22
PCT/US2015/026876 WO2015164374A1 (en) 2014-04-22 2015-04-21 Irak inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2016013668A true MX2016013668A (es) 2017-01-20

Family

ID=54333088

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013668A MX2016013668A (es) 2014-04-22 2015-04-21 Inhibidores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.

Country Status (11)

Country Link
US (1) US20150329498A1 (es)
EP (1) EP3134091A4 (es)
JP (1) JP2017513954A (es)
KR (1) KR20160145803A (es)
CN (1) CN106413715A (es)
BR (1) BR112016024414A2 (es)
CA (1) CA2945819A1 (es)
MX (1) MX2016013668A (es)
RU (1) RU2016140870A (es)
TW (1) TW201625556A (es)
WO (1) WO2015164374A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9926330B2 (en) 2014-09-30 2018-03-27 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP3200787B1 (en) * 2014-09-30 2019-09-04 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
AU2016333987A1 (en) 2015-10-05 2018-05-10 Ny State Psychiatric Institute Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
SG10201508795XA (en) * 2015-10-23 2017-05-30 Agency Science Tech & Res Method for treating cancer
JP2019519485A (ja) 2016-05-04 2019-07-11 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
WO2017205762A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
KR20180049632A (ko) 2016-11-03 2018-05-11 현대모비스 주식회사 차량용 라이트 가이드 유닛
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2018226230A1 (en) * 2017-06-08 2018-12-13 The Children's Medical Center Corporation Compounds and methods for treatment of diamond blackfan anemia
CN108558854A (zh) * 2017-06-10 2018-09-21 曹艳 一种治疗革兰氏阳性菌引起的感染的药物及其合成方法
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5883681A (en) * 1981-11-12 1983-05-19 Sankyo Co Ltd 4-cycloalkylaminoquinazoline derivative
DE4208254A1 (de) * 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4308014A1 (de) * 1993-03-13 1994-09-15 Hoechst Schering Agrevo Gmbh Kondensierte Stickstoffheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
AU1631699A (en) * 1997-12-18 1999-07-05 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
CA2877786A1 (en) * 2012-06-26 2014-01-03 Bayer Pharma Aktiengesellschaft N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
WO2014011911A2 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
CN106413715A (zh) 2017-02-15
EP3134091A4 (en) 2017-08-30
TW201625556A (zh) 2016-07-16
BR112016024414A2 (pt) 2017-08-15
JP2017513954A (ja) 2017-06-01
US20150329498A1 (en) 2015-11-19
KR20160145803A (ko) 2016-12-20
WO2015164374A1 (en) 2015-10-29
EP3134091A1 (en) 2017-03-01
CA2945819A1 (en) 2015-10-29
RU2016140870A (ru) 2018-05-23

Similar Documents

Publication Publication Date Title
DK3119884T3 (da) Serinproteaser af bacillus-arter
PH12016501763A1 (en) Multispecific antibodies
WO2014145490A3 (en) Breeding, production, processing and use of specialty cannabis
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
PH12016502177A1 (en) Processes of preparing a jak1 inhibitor and new forms thereto
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
WO2016034591A3 (en) Mutant csgg pores
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12016501546A1 (en) Cyclopropylamines as lsd1 inhibitors
PH12015502028A1 (en) Ido inhibitors
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
PH12018500907A1 (en) Inhibitors of ret
MX2017010673A (es) Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
MX2016012470A (es) Derivados quinolina como inhibidores smo.
WO2014172644A3 (en) Bicyclic heterocycles as fgfr inhibitors